What is the AGN.CN share price today?

This page shows the latest available Algernon Pharmaceuticals Inc. (AGN.CN) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is Algernon Pharmaceuticals Inc. listed?

Algernon Pharmaceuticals Inc. trades on the Canadian Securities Exchange under the symbol AGN.CN, ISIN CA01559C1068.

How large is Algernon Pharmaceuticals Inc.?

Its market capitalisation is approximately 157.52K CAD, based on the latest available price and share count from our data provider.

Canadian Securities Exchange (CSE) · AGN.CN · ISIN CA01559C1068

Algernon Pharmaceuticals Inc.

No trading activity has been reported for this listing since April 17, 2026. It may be delisted, halted or inactive.

0.0450 CAD

April 17, 2026

Algernon Pharmaceuticals Inc. (AGN.CN) trades on the Canadian Securities Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 157.52K CAD. The company reports around 5 employees. Its ISIN is CA01559C1068. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Canadian Securities Exchange (CSE)

ISIN

CA01559C1068

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

157.52K CAD

Employees

Previous close

0.04 CAD

Day range

0.04 – 0.04

52-week range

0.04 – 1.00

Volume

2.17K

50-day average

0.45 CAD

200-day average

0.64 CAD

Asset type

Equity

About Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Company website

Frequently asked

What is the AGN.CN share price today?: This page shows the latest available Algernon Pharmaceuticals Inc. (AGN.CN) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is Algernon Pharmaceuticals Inc. listed?: Algernon Pharmaceuticals Inc. trades on the Canadian Securities Exchange under the symbol AGN.CN, ISIN CA01559C1068.
How large is Algernon Pharmaceuticals Inc.?: Its market capitalisation is approximately 157.52K CAD, based on the latest available price and share count from our data provider.

All Algernon Pharmaceuticals Inc. data comes from exchange and provider feeds for the Canadian Securities Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.